Imidazoline scaffold in medicinal chemistry: a patent review (2012-2015) [0.03%]
药物化学中的咪唑啉支架专利回顾（2012-2015）
Franciszek Sączewski,Anita Kornicka,Łukasz Balewski
Franciszek Sączewski
Introduction: Until very recently, the 'imidazoline drugs' were perceived as a class of central and/or peripheral sympatholytics and vasodilators acting at either the imidazoline binding sites and/or α-adrenergic recepto...
DNA methyltransferase inhibitors: an updated patent review (2012-2015) [0.03%]
DNA甲基转移酶抑制剂的专利回顾(2012-2015)更新版
Pan Xu,Guang Hu,Cheng Luo et al.
Pan Xu et al.
Introduction: DNA methyltransferases (DNMTs), important enzymes involved in epigenetic regulation of gene expression, represent promising targets in cancer therapy. DNMT inhibitors (DNMTi), which can modulate the aberrant...
Detection and treatment of Trypanosoma cruzi: a patent review (2011-2015) [0.03%]
恰加斯病原虫的检测与治疗专利回顾(2011-2015)
Juan B Rodriguez,Bruno N Falcone,Sergio H Szajnman
Juan B Rodriguez
Introduction: Trypanosoma cruzi is the etiologic agent of American trypanosomiasis (Chagas disease), which is one of the important parasitic diseases worldwide. The number of infected people with T. cruzi diminished from ...
Inhibitors of programmed cell death 1 (PD-1): a patent review (2010-2015) [0.03%]
程序性细胞死亡1(PD-1)抑制剂专利回顾(2010-2015)
Tryfon Zarganes-Tzitzikas,Markella Konstantinidou,Yongzhi Gao et al.
Tryfon Zarganes-Tzitzikas et al.
Proprotein convertase subtilisin / kexin 9 (PCSK9) inhibitors and the future of dyslipidemia therapy: an updated patent review (2011-2015) [0.03%]
用于治疗脂质异常的新型药物前蛋白转化酶枯草杆菌肽9抑制剂及未来专利回顾(2011-2015)
Sandy Elbitar,Petra El Khoury,Youmna Ghaleb et al.
Sandy Elbitar et al.
The identification by Abifadel et al. in 2003 of the first mutations of PCSK9 was the major breakthrough in the cholesterol field that led to a new therapeutic target. This discovery paved the way to new lipid lowering drugs reducing LDL-ch...
Leewanshi Chakrawarti,Rishab Agrawal,Shweta Dang et al.
Leewanshi Chakrawarti et al.
Introduction: Green tea contains polyphenolic flavanoids such as epigallocatechin-3- gallate (EGCG), epicatechin-3-gallate (ECG), epigallocatechin (EGC) and epicatechin (EC). EGCG is the most abundant and active compound ...
Polymers, scaffolds and bioactive molecules with therapeutic properties in osteochondral pathologies: what's new? [0.03%]
具有治疗作用的聚合物、支架和生物活性分子在骨软骨病变中的最新进展
Elena López-Ruiz,Gema Jiménez,María Ángel García et al.
Elena López-Ruiz et al.
Introduction: Despite clinical efforts, treatments to heal osteochondral lesions remain inefficient and frequently result, long-term, in joint arthroplasty. The complex structure of cartilage tissue, composed of a highly ...
Therapeutic use of selective synthetic ligands for retinoic acid receptors: a patent review [0.03%]
维甲酸受体选择性配体的药物应用：专利点评
Aleksandra Marchwicka,Alan Cunningham,Ewa Marcinkowska et al.
Aleksandra Marchwicka et al.
Introduction: Differentiation therapy using all-trans retinoic acid (ATRA) revolutionised the treatment of acute promyelocytic leukaemia to such an extent that it is now one of the most curable types of leukaemia, with AT...
Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present) [0.03%]
选择性磷酸二酯酶2A(PDE2A)抑制剂的专利回顾(2010-至今)
Andrés A Trabanco,Peter Buijnsters,Frederik J R Rombouts
Andrés A Trabanco
Introduction: The cyclic nucleotides cAMP and cGMP are ubiquitous intracellular second messengers regulating a large variety of biological processes. The intracellular concentration of these biologically relevant molecule...
Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015) [0.03%]
interleukin-1受体相关激酶4(IRAK4)抑制剂专利回顾(2012-2015)
W Michael Seganish
W Michael Seganish
Introduction: IRAK4 is located proximal to TLR/IL-1 receptors, and in preclinical studies, inhibits downstream signaling from these receptors. The development of novel small molecule inhibitors of this kinase has the pote...